Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation

Completed · Phase 4

Conditions studied: End-Stage Renal Disease, Living Donors

In brief

The purpose of this study is to observe in a randomized prospective study the effectiveness and toxicity of Thymoglobulin vs. Campath-1H used for induction therapy in recipients of living donor (LD) kidneys, compared with the investigators standard treatment protocol of Zenapax® and maintenance immunosuppression.

Key facts

Study ID

NCT01046955

Run by

University of Miami

People needed

38

Starts

2005-11-01

Expected to finish

2008-12-01

Last updated by the study team

2010-01-12

Who can join

Age: 14 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >14 years
• Weight >40 kg
• Primary renal allograft:living related (non HLA identical) and unrelated donor
• Negative standard cross match for T-cells
• Signed and dated consent form

You may not qualify if…

• Patient has previously received or is receiving an organ transplant other than kidney
• Patient has received a kidney transplant from a non-heart beating donor
• Patient has received an ABO incompatible donor kidney
• Recipient or donor is seropositive for human immunodeficiency virus (HIV)
• Patient has a current malignancy or a history of malignancy

Where it is running

• University of Miami Jackson Memorial Hospital — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.